Medtronic (NYSE:MDT) Stock

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. analyst Swayampakula Ramakanth upgraded the rating for Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) from Neutral to Buy and announced a $3 price target. Vor Biopharma shares closed at $1.06 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Brad Reback upgraded Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) from Hold to Buy and raised the price target from $180 to $250. Oracle shares closed at $210.24 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Mike Polark upgraded Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Underperform to Peer Perform. Medtronic shares closed at $86.02 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst James Heaney upgraded the rating for The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) from Hold to Buy and raised the price target from $100 to $144. Walt Disney shares closed at $122.34 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Longbow Research analyst David Macgregor upgraded Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) from Neutral to Buy and announced a $145 price target. Whirlpool shares closed at $96.17 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ORCL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ORCL/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30125417/image-444-1024x583.png" alt="" class="wp-image-967311" style="width:625px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30125417/image-444-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30125417/image-444-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30125417/image-444-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30125417/image-444.png 1127w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46136470/jim-cramer-just-revealed-1-oil-stock-he-actually-wants-to-own">Jim Cramer Just Revealed 1 Oil Stock He Actually Wants To Own</a></li>
</ul>
Photo via Shutterstock

News

Upgrades

Markets

Analyst Ratings

Trading Ideas

ORCL

This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $97.5, along with a high estimate of $110.00 and a low estimate of $90.00. This upward trend is evident, with the current average reflecting a 0.93% increase from the previous average price target of $96.60.
<img src="https://www.benzinga.com/files/images/story/2025/1751288428_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Medtronic by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$101.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$90.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$91.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Medtronic. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Medtronic's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Medtronic's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Medtronic analyst ratings.</a>
<h2>About Medtronic</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
<h3>Understanding the Numbers: Medtronic's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Medtronic's remarkable performance in 3M is evident. As of 30 April, 2025, the company achieved an impressive revenue growth rate of 3.94%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Medtronic's net margin is impressive, surpassing industry averages. With a net margin of 11.83%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Medtronic's ROE stands out, surpassing industry averages. With an impressive ROE of 2.17%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Medtronic's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.16% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average at 0.59, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 6 Analysts Discuss Medtronic Stock

Wolfe Research analyst Mike Polark upgrades Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Underperform to Peer Perform.

Wolfe Research Upgrades Medtronic to Peer Perform

Doctors used to be the <a href="https://www.benzinga.com/personal-finance/25/03/44481583/bill-gates-thinks-you-might-only-work-2-3-days-a-week-thanks-to-ai-but-also-says-legitimately-people-are-like-wow-this-is-a-bit-scary">gold standard of job security</a>. After all, you can't outsource a heart transplant to a chatbot… right?
But according to Elon Musk, even the most elite surgeons might want to start looking over their scrub-covered shoulders.
"Robots will surpass good human surgeons within a few years and the best human surgeons within ~5 years," he <a href="https://x.com/elonmusk/status/1916573094367625556">posted on X in April</a>.
Don't Miss:
<ul class="wp-block-list">
<li>GoSun's breakthrough rooftop EV charger already has 2,000+ units reserved —<a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor"> become an investor in this $41.3M clean energy brand today</a>.</li>
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market.<a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment"> Back a bold new approach to cancer treatment with high-growth potential.</a></li>
</ul>
That might sound like a stretch — but Musk pointed to <a href="https://www.benzinga.com/markets/tech/25/06/46012959/elon-musks-neuralink-implants-brain-chip-in-6th-patient-enables-paralyzed-man-to-move-cursor-play-game-with-his-mind">real-world experience at Neuralink</a>. "It was impossible for a human to achieve the required speed and precision," he said, referring to why his neurotechnology company had to rely on a robot to insert brain-computer electrodes.
Neuralink's surgical robot is designed to place ultra-thin threads into the brain, a job too delicate for even the steadiest hands. Musk wasn't just speculating — he was citing the kind of tech already in use.
And the broader field of robot-assisted surgery has been gaining momentum. Around the same time as Musk's post, Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) in April <a href="https://news.medtronic.com/2025-04-26-Medtronic-Expand-URO-U-S-clinical-trial-meets-safety-and-effectiveness-primary-endpoints-for-Hugo-TM-robotic-assisted-surgery-system">released results</a> from 137 live surgeries using its Hugo robotic system. The complication rate was just 3.7% for prostate procedures, with the system exceeding success benchmarks by a wide margin.
So what's the problem? According to actual surgeons: nuance, context — and a reality check.
One American neurosurgeon responded directly to Musk's claim on X, <a href="https://x.com/DrSAdusumilli/status/1916612237558419743">saying</a>:
"This is false. As a neurosurgeon, I promise you that no &#8220;robot&#8221; surgeon can EVER autonomously perform brain and spine surgery or likely any surgeries effectively, appropriately or safely. Too many variables require critical thinking."
Another <a href="https://x.com/dr_francisco79/status/1916600843987546183">surgeon chimed in writing</a>: "The problem is that the human body is not a machine and, in surgery in particular, the unexpected happens all the time."
He added, "At this point, the surgeon needs to use creativity to solve problems, and that is what separates the best from the average."
Another robotic surgeon, who claims to have&nbsp; performed more than 2,400 procedures, <a href="https://x.com/DrSAdusumilli/status/1916612237558419743">posted</a>:
"Misleading!! Robots are not actually doing the surgery; the surgeon is doing it with the console. They are great tools, but not surgeons."
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, with minimum investments as low as $100</a>.
Leaders in outpatient surgery centers echoed those concerns to<a href="https://ascnews.com/2025/04/ai-surgery-debate-heats-up-after-elon-musks-robot-prediction/"> Ambulatory Surgery Center News</a>.
Wes Battiste, CEO of Destin Surgery Center, pushed back diplomatically:
"I admire Elon Musk as an exceptional entrepreneur and visionary. But I would beg to differ with him in regard to his recent post referencing AI replacing surgeons in the next five years."
Battiste emphasized that while AI excels at analyzing patterns, surgery involves subjective decisions and unpredictable anatomy — the kind that doesn't always match textbook diagrams.
"Medicine is called an art and not a science for a reason," he said.
Others, like Michael McClain of Left Coast Healthcare Advisors, warned of regulation lagging behind AI's capabilities:&nbsp;
"There is a ton of work to do in terms of safety, reliability, liability and governance before truly autonomous surgery is a remote possibility."
Robotic systems will absolutely keep playing a bigger role in operating rooms. But for now, most experts agree they're still just tools — not replacements.
Joan Dentler, founder of Avanza Healthcare Strategies, summed up what many doctors were thinking when she told ASCN:
"I'm not sure that the technology will fully replace human surgeons. Perhaps it will augment their abilities."
There are still a few years to go before we find out whether Musk's prediction is prophetic, premature, or just another bold headline. But either way, the conversation isn't just theoretical anymore. Robots are already in the operating room—and the question now is how much further they're allowed to go.
See Next:
<ul class="wp-block-list">
<li>$100k in assets? Maximize your retirement and cut down on taxes:<a href="https://www.benzinga.com/money/wideradvisor-retirement-planning"> Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>

Personal Finance

Elon Musk Says Robots Will Outperform 'Best Human Surgeons' in 5 Years — But Doctors Beg To Differ: Humans Aren't Built Like Car Parts

The <a href="https://www.benzinga.com/topic/fda-0">U.S. Food and Drug Administration</a> (FDA) is aware that Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and its subsidiary, Given Imaging Inc., have issued two letters to affected customers recommending that certain Bravo CF Capsule Delivery Devices be removed from where they are used and sold.
What Happened: Earlier in June, Medtronic <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-esophageal-ph-monitoring-capsule-issue-medtronic" rel="noreferrer noopener">sent</a> all affected customers an "URGENT: MEDICAL DEVICE RECALL" letter. An updated letter was sent on June 16.
Medtronic on Tuesday stated that the capsule may not attach to the patient's esophagus or detach from the delivery device as intended due to a misapplication of the adhesive during manufacturing the Bravo CF capsule delivery device.
Risks associated with this issue include patient aspiration/inhalation, perforation of the esophagus, airway obstruction, hemorrhage/blood loss/bleeding, laceration of the esophagus, a delay in diagnosis, and foreign bodies remaining in the patient.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45932090/limited-impact-on-intuitive-surgical-from-reprocessed-robotic-instruments-analyst" rel="noreferrer noopener">Limited Impact On Intuitive Surgical From Reprocessed Robotic Instruments: Analyst</a>
Why It Matters: Medtronic has reported 33 serious injuries and no deaths associated with this issue.
The Bravo system is designed to place and attach a pH monitoring capsule to the esophagus, recording pH data to assist a physician in diagnosing clinical gastroesophageal reflux.
The Bravo system involves placing a pH capsule against the mucosal wall of the esophagus, simultaneously measuring pH, and transmitting the data to a recorder attached to the patient's waist.
The patient interacts with the recorder to indicate symptoms, allowing the physician to compare the patients' symptoms to the occurrence of the reflux episodes.
Additionally, on Monday, the FDA <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/medical-procedure-kits-correction-medline-industries-lp-issues-correction-medline-procedure-kits" rel="noreferrer noopener">said</a> that Medtronic&#8217;s subsidiary, Medline Industries, LP, sent all affected customers an Immediate Action Required Medical Device Recall notice in February.
Medline Industries LP is correcting certain lots of their medical procedure kits containing recalled Medtronic Aortic Root Cannulas due to the potential for excess material in the male luer. 
Medline is providing a sticker to attach to the procedure kits, notifying the user not to use the aortic root cannula within the procedure kit and to use an aortic root cannula from another supplier.
The use of the affected products may cause serious adverse health consequences, including procedure delay, neurological deficits/stroke (reversable and irreversible), and death. &nbsp;&nbsp;
&nbsp;At this time, Medline Industries has reported no serious injuries or deaths related to this issue.
Medline medical procedure kits containing Medtronic Aortic Root Cannulas are convenience kits used for various medical procedures.
The Medtronic Aortic Root Cannula in the kit is used for six hours or less during surgery with the heart-and-lung machine (cardiopulmonary bypass). The cannula may also be used to remove air from the major artery (aorta) when a bypass procedure is finished.
Price Action: MDT stock is up 0.3% at $86.36 at the last check on Wednesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/46098062/paychex-stock-takes-a-hit-as-margin-squeeze-overshadows-outlook" target="_blank" rel="noreferrer noopener">Paychex Stock Takes A Hit As Margin Squeeze Overshadows Outlook</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

General

FDA Sounds Alarm After 33 Injuries Tied To Medtronic Device Malfunction

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-esophageal-ph-monitoring-capsule-issue-medtronic" title="https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-esophageal-ph-monitoring-capsule-issue-medtronic">https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-esophageal-ph-monitoring-capsule-issue-medtronic</a>

Biotech

FDA Says Aware Medtronic & Given Imaging Issued Two Letters To Affected Customers Recommending Certain Bravo Cf Capsule Delivery Devices Be Removed; Medtronic Has Reported 33 Serious Injuries And No Deaths Associated With This Issue

<a href="https://x.com/SarahKarlin/status/1937539272392733011 " title="https://x.com/SarahKarlin/status/1937539272392733011 ">https://x.com/SarahKarlin/status/1937539272392733011&nbsp;</a>

DXCM

GCTK

MASI

SENS

TNDM

WLDS

Watching Stocks Involved In Wearable Health Devices; Traders Circulate X Post Saying "RFK says HHS about to launch one of the biggest campaigns in HHS history to encourage Americans to use wearable health devices (like CGMs). his vision is every American wearing "wearable" in 4 years... HUGE COIs here with some of his top advisors & their businesses."

Medtronic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has fallen 42.06% since its last report. The company recently reported that it has 7.88 million shares sold short, which is 0.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750435219_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medtronic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 5.33%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Medtronic's Recent Short Interest

Leerink Partners analyst Mike Kratky initiates coverage on Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform rating and announces Price Target of $110.

Price Target

Initiation

Leerink Partners Initiates Coverage On Medtronic with Outperform Rating, Announces Price Target of $110

Bank of America Securities connected with Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) on reprocessing &#8220;noise&#8221; in the market.
Analyst Travis Steed highlighted that reprocessing is not new to Intuitive, even though it might seem like new news to some investors.
What Happened: For the unversed, in March this year, Restore Robotics received 510(k) <a target="_blank" href="https://www.prnewswire.com/news-releases/restore-robotics-receives-fda-510k-clearance-for-remanufacturing-da-vinci-xi-8mm-monopolar-curved-scissors-302409135.html" rel="noreferrer noopener">clearance</a> from the U.S. Food and Drug Administration (FDA) for remanufacturing Intuitive Surgical&#8217;s Da Vinci Xi Monopolar Scissors as of March 11, 2025, through its subsidiary Iconocare Health.
In a statement, Restore Robotics said it is offering hospitals and surgery centers a cost-effective and sustainable alternative to purchasing instruments from the original manufacturer.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966347/analysts-remain-bullish-on-intuitive-surgical-despite-macro-uncertainty" rel="noreferrer noopener">Analysts Remain Bullish On Intuitive Surgical Despite Macro Uncertainty</a>
In May, Restore Robotics announced that Dr. Eugene Dickens at Hillcrest Medical Center in Tulsa, Oklahoma, conducted the first in-human use of a remanufactured da Vinci&nbsp; Xi robotic instrument on a patient using the newest model robotic surgical system, the da Vinci 5.
In addition, Panama City Surgery Center performed the first in-human use on a da Vinci Xi, which is the workhorse of the da Vinci robotics surgical systems.
Restore Robotics <a target="_blank" href="https://www.prnewswire.com/news-releases/first-in-human-use-of-remanufactured-da-vinci-xi-robotic-instruments-302467048.html" rel="noreferrer noopener">said</a> it is working on getting clearances for other da Vinci robotic instruments.
Why It Matters: Deutsche Bank downgraded Intuitive Surgical from Hold to Sell on Monday, lowering the price forecast from $515 to $440.
BofA analyst Steed noted that some companies have offered services for Intuitive&#8217;s surgical robots and sold remanufactured instruments for years.
Intuitive does not ban third-party remanufactured instruments as long as they have received 510(k) clearance or a similar approval from the FDA.
The company also clarified that it won&#8217;t cancel service contracts, stop doing business, or consider it a contract violation if a U.S. customer uses these FDA-cleared, third-party instruments.
On Friday, BofA maintained the Buy rating with a <a href="https://www.benzinga.com/quote/ISRG/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $650</a> and sees continued potential upside to Street estimates.
&#8220;One thing that gives us some comfort that reprocessing will only be a small share of the market over the long term is reprocessing today is only a small low single-digit percent headwind on Medtronic Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) global surgical business and its isolated mostly in its US vessel sealing and dissection product lines.&#8221;
BofA thinks reprocessing in robotic instruments will only be a small share of customers and tries to innovate accordingly.
On Wednesday, an analyst note by William Blair on this development suggested that hospitals investing millions of dollars in a robotics program will take a pause at operating outside the Intuitive Surgical ecosystem.
The high cost and critical nature of these surgical investments make operating outside of Intuitive&#8217;s established and supported ecosystem a significant risk for healthcare providers, the note added.
Currently, the threat is considered minimal as only one third-party instrument has received FDA clearance, and Intuitive does not offer direct support for such products. While the analyst acknowledged this as a potential long-term risk to watch, the immediate impact is expected to be limited.
Therefore, despite negative headlines that could cause short-term volatility for the premium-valued stock (cited at 57 times 2026 EPS), analyst Brandon Vazquez of William Blair maintains an Outperform rating on the company.
Price Action: ISRG stock is trading lower by 0.72% to $516.70&nbsp;at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45540768/medtronic-beats-q4-forecasts-hikes-dividend-plans-diabetes-spinoff" target="_blank" rel="noreferrer noopener">Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff</a></li>
</ul>
Image via Shutterstock

Analyst Color

ISRG

Limited Impact On Intuitive Surgical From Reprocessed Robotic Instruments: Analyst

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) announced on May 21 its plans to separate its Diabetes business into a separate, publicly traded company. The separation will occur via a two step transaction &#8211; an initial minority IPO carve-out followed by a split-off of the remaining stake. The separation will be tax-free for the shareholders and is expected to be completed in the next 18 months.
The separation comes as Medtronic focuses on higher-margin, faster-growing businesses such as pulsed field ablation and renal denervation. The Diabetes segment, which contributed $2.75 billion or 8% of FY2025 revenue, has lagged behind peers in growth and profitability, facing stiff competition from companies like Dexcom (DXCM), Abbott (ABT), and Tandem Diabetes Care (TNDM).
Strategic Rationale
Diabetes business is predominantly B2C, while Medtronic operates mainly in the B2B space. This implies that both businesses sell different types of products to different types of customers. As such, there are limited synergies between the businesses which justify the argument for separation.
With the spin-off, the diabetes unit, dubbed "SpinCo," will gain operational autonomy and flexibility to scale up R&amp;D and commercial efforts.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="605" height="161" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100846/Details.png" alt="" class="wp-image-14339" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100846/Details.png 605w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100846/Details-300x80.png 300w" sizes="(max-width: 605px) 100vw, 605px" /></figure>
Valuation Despite past underperformance, the Diabetes business is showing signs of a turnaround, growing 10.7% year-over-year in FY2025. GSBR Research estimates the standalone DiabetesCo could be valued between $8 billion and $11 billion, depending on market sentiment and growth execution.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="457" height="143" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100917/Spin.png" alt="" class="wp-image-14340" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100917/Spin.png 457w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100917/Spin-300x94.png 300w" sizes="(max-width: 457px) 100vw, 457px" /></figure>
Medtronic's core business &#8211; excluding Diabetes &#8211; generated nearly $31 billion in FY2025 revenue, and are characterized by higher margins. Post spin, the portfolio will become even more focused on high margin growth markets such as pulse (PFA) and renal denervation. This is expected to expand operating margins by 100 bps.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="500" height="201" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100928/MedexSpin.png" alt="" class="wp-image-14341" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100928/MedexSpin.png 500w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100928/MedexSpin-300x121.png 300w" sizes="(max-width: 500px) 100vw, 500px" /></figure>
Bottom line: The diabetes spin-off will unlock value for both Medtronic and the SpinCo. Medtronic (ex-Diabetes) will become a higher-margin company. The spin-off could also trigger a re-rating of Medtronic shares, as investors reassess its streamlined profile. Meanwhile, the diabetes business will gain greater autonomy and flexibility to aggressively invest in its innovation pipeline. The Diabetes business could trade in the range of 3-4x P/S multiple and as such could potentially be valued between $8-$11 billion.

Long Ideas

IPOs

Opinion

Medtronic Is Separating Its Diabetes Business - Good News For Investors

Medtronic Announces MiniMed As Name For Planned New Diabetes Company Following Intended Separation

Analysts' ratings for Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Medtronic and provided 12-month price targets. The average target is $95.25, accompanied by a high estimate of $101.00 and a low estimate of $90.00. Observing a downward trend, the current average is 2.81% lower than the prior average price target of $98.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1749211243_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Medtronic among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$101.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$90.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Medtronic's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Medtronic analyst ratings.</a>
<h2>Get to Know Medtronic Better</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
<h3>Financial Insights: Medtronic</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Medtronic's revenue growth over a period of 3M has been noteworthy. As of 30 April, 2025, the company achieved a revenue growth rate of approximately 7.66%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Medtronic's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Medtronic's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.17% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Medtronic's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average. With a ratio of 0.59, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Medtronic: 4 Analysts Share Their Views

Needham analyst Mike Matson reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Medtronicto Hold

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected" title="https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected">https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected</a>.

'Flexible Tracheostomy Tube Recall: Medtronic Removes Shiley Adult Flexible Tracheostomy Tube with TaperGuard Cuff Reusable Inner Cannula Due to Risk for Disconnection of the Flange from the Device Cannula' - FDA

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$55.00</td>
<td>$71.1K</td>
<td>2.1K</td>
<td>1.3K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$25.00</td>
<td>$68.0K</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$100.00</td>
<td>$44.0K</td>
<td>1.1K</td>
<td>960</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$630.00</td>
<td>$119.6K</td>
<td>6</td>
<td>705</td>
</tr>
<tr>
<td>VEEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$210.00</td>
<td>$65.7K</td>
<td>534</td>
<td>589</td>
</tr>
<tr>
<td>NVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$115.00</td>
<td>$28.0K</td>
<td>1.8K</td>
<td>379</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$80.00</td>
<td>$42.5K</td>
<td>883</td>
<td>372</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$295.00</td>
<td>$40.2K</td>
<td>985</td>
<td>344</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$195.00</td>
<td>$25.8K</td>
<td>5.0K</td>
<td>319</td>
</tr>
<tr>
<td>COR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$280.00</td>
<td>$36.4K</td>
<td>762</td>
<td>200</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a put option sweep that happens to be bearish, expiring in 51 day(s) on July 18, 2025. This event was a transfer of 89 contract(s) at a $55.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $71.1K, with a price of $799.0 per contract. There were 2196 open contracts at this strike prior to today, and today 1320 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 1000 contract(s) at a $25.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $68.0K, with a price of $68.0 per contract. There were 2289 open contracts at this strike prior to today, and today 1083 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a put option trade that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 958 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $44.0K, with a price of $46.0 per contract. There were 1139 open contracts at this strike prior to today, and today 960 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with neutral sentiment. It expires in 51 day(s) on July 18, 2025. Parties traded 46 contract(s) at a $630.00 strike. The total cost received by the writing party (or parties) was $119.6K, with a price of $2600.0 per contract. There were 6 open contracts at this strike prior to today, and today 705 contract(s) were bought and sold. 
• Regarding VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we observe a put option sweep with bearish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 212 contract(s) at a $210.00 strike. This particular put needed to be split into 45 different trades to become filled. The total cost received by the writing party (or parties) was $65.7K, with a price of $310.0 per contract. There were 534 open contracts at this strike prior to today, and today 589 contract(s) were bought and sold. 
• For NVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), we notice a call option sweep that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 224 contract(s) at a $115.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $125.0 per contract. There were 1879 open contracts at this strike prior to today, and today 379 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option trade that happens to be bearish, expiring in 79 day(s) on August 15, 2025. This event was a transfer of 100 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $42.5K, with a price of $425.0 per contract. There were 883 open contracts at this strike prior to today, and today 372 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option trade with bullish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 134 contract(s) at a $295.00 strike. The total cost received by the writing party (or parties) was $40.2K, with a price of $300.0 per contract. There were 985 open contracts at this strike prior to today, and today 344 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 137 contract(s) at a $195.00 strike. The total cost received by the writing party (or parties) was $25.8K, with a price of $189.0 per contract. There were 5038 open contracts at this strike prior to today, and today 319 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a put option sweep with neutral sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 135 contract(s) at a $280.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $36.4K, with a price of $270.0 per contract. There were 762 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

AMGN

GILD

MRNA

REGN

VEEV

10 Health Care Stocks Whale Activity In Today's Session

Benzinga examined the prospects for<a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener"> many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
U.S. markets experienced heightened volatility this week as President Donald Trump intensified trade tensions by threatening a 25% tariff on foreign-made Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) products and announcing a 50% tariff on European Union imports starting June 1. These announcements led to a decline in major indices, with the S&amp;P 500 falling 0.7%, the Dow Jones dropping 0.6%, and the Nasdaq decreasing by 1%. Apple shares were particularly affected, losing 3% in value.
Investor concerns over the U.S. fiscal outlook grew as the 30-year Treasury yield briefly surpassed 5.15%, reflecting apprehensions about rising deficits and debt sustainability. A weak 20-year Treasury auction further exacerbated these fears, indicating diminished demand for long-term U.S. debt.
Looking ahead, market participants are closely monitoring upcoming U.S.-China trade negotiations and potential adjustments to existing tariffs. The Federal Reserve's stance on interest rates remains a focal point, especially as real borrowing costs rise, tightening broader financial conditions. Additionally, corporate earnings reports and economic indicators will continue to influence market dynamics in the coming weeks.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/trading-ideas/technicals/25/05/45544614/google-could-smart-glasses-smart-speech-spark-the-stocks-next-big-leap">"Google: Could smart glasses, speech spark the stock's next big leap?"</a>, by Surbhi Jain, reports that Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) is gaining investor attention as its partnership with Warby Parker to develop AI-powered smart glasses and advancements in speech recognition technology signal a potential new growth narrative beyond search.
<a href="https://www.benzinga.com/government/regulations/25/05/45574763/goldman-sachs-defense-stock-golden-dome">"Goldman Sachs: Golden Dome is big win for this defense stock"</a>, by Piero Cingari, reports that Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) analyst Noah Poponak reiterated a Buy rating on L3Harris Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>), highlighting its potential to secure billions in contracts from the Trump administration's $175 billion "Golden Dome" missile defense initiative.
<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45531583/amd-nvidia-shares-jump-after-musk-highlights-xais-gpu-needs-we-expect-to-still-buy-a-lot">"AMD, Nvidia shares jump after Musk highlights xAI's GPU needs: ‘We expect to still buy a lot'"</a>, by Adam Eckert, reports that Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares rose after Elon Musk stated that Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and xAI plan to purchase "a lot" of GPUs from both companies to support AI initiatives like robotaxis and the Optimus robot.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45541780/d-wave-quantum-stock-extends-rally-as-momentum-builds-following-launch-of-new-quantum-system">D-Wave Quantum Stock Extends Rally As Momentum Builds Following Launch Of New Quantum System</a>
<a href="https://www.benzinga.com/25/05/45517783/magnificent-7-stun-the-street-with-the-best-earnings-beat-since-2021">Magnificent 7 Stun The Street With Best Earnings Beat Since 2021</a>
<a href="https://www.benzinga.com/25/05/45540768/medtronic-beats-q4-forecasts-hikes-dividend-plans-diabetes-spinoff">Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff</a>

The Bears
<a href="https://www.benzinga.com/news/legal/25/05/45568107/solar-energy-stocks-drop-as-house-approves-major-rollback-of-climate-incentives">"Solar energy stocks drop as House approves major rollback of climate incentives"</a>, by Erica Kollmann, reports that Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares fell after the House passed President Trump's "One Big, Beautiful Bill," which rolls back key climate incentives, leaving the solar industry facing uncertainty as the bill moves to the Senate.
<a href="https://www.benzinga.com/25/05/45540759/target-stock-slips-as-q1-earnings-miss-estimates-fy2025-outlook-cut-amid-slowing-sales">"Target stock slips as Q1 earnings miss estimates, FY2025 outlook cut amid slowing sales"</a>, by Nabaparna Bhattacharya, reports that Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) shares fell after the company missed Q1 earnings expectations and lowered its FY2025 outlook, citing a 3.8% drop in comparable sales driven by tariffs, weakened consumer sentiment, and backlash from scaling back diversity, equity, and inclusion initiatives.
<a href="https://www.benzinga.com/news/rumors/25/05/45555558/wolfspeed-stock-plunges-59-on-bankruptcy-fears-options-traders-cash-in">"Wolfspeed stock plunges 59% on bankruptcy fears: Options traders cash in"</a>, by Erica Kollmann, reports that Wolfspeed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares plummeted 59% to $1.28 after reports emerged that the company is preparing to file for Chapter 11 bankruptcy, with options traders profiting from heavy put activity ahead of the news.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/government/regulations/25/05/45554854/health-care-stocks-like-unitedhealth-cvs-tank-on-wednesday-heres-why">Health Care Stocks Like UnitedHealth, CVS Tank On Wednesday: Here's Why</a>
<a href="https://www.benzinga.com/25/05/45567780/hims-hers-health-stock-is-tumbling-thursday-whats-happening">Hims &amp; Hers Health Stock Is Tumbling Thursday: What's Happening?</a>
<a href="https://www.benzinga.com/markets/equities/25/05/45532892/legendary-investor-jeremy-grantham-warns-of-50-stock-market-crash">Legendary Investor Jeremy Grantham Warns Of 50% Stock Market Crash</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

AAPL

GOOGL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

NVDA

QBTS

TSLA

WOLF

Benzinga Bulls And Bears: Alphabet, L3Harris, Target — And Latest Tariff News Roils Markets

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/23/25</td>
<td>$300.00</td>
<td>$25.7K</td>
<td>6.4K</td>
<td>7.0K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$76.00</td>
<td>$244.0K</td>
<td>10</td>
<td>4.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$1000.00</td>
<td>$25.6K</td>
<td>361</td>
<td>274</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$400.00</td>
<td>$52.8K</td>
<td>46</td>
<td>15</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$450.00</td>
<td>$30.4K</td>
<td>93</td>
<td>6</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be neutral, expiring in 1 day(s) on May 23, 2025. This event was a transfer of 60 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $25.7K, with a price of $429.0 per contract. There were 6422 open contracts at this strike prior to today, and today 7074 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option trade that happens to be bullish, expiring in 36 day(s) on June 27, 2025. This event was a transfer of 4000 contract(s) at a $76.00 strike. The total cost received by the writing party (or parties) was $244.0K, with a price of $61.0 per contract. There were 10 open contracts at this strike prior to today, and today 4000 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 85 day(s) on August 15, 2025. Parties traded 54 contract(s) at a $1000.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.6K, with a price of $475.0 per contract. There were 361 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bullish, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 12 contract(s) at a $400.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $52.8K, with a price of $4400.0 per contract. There were 46 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be neutral, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 5 contract(s) at a $450.00 strike. The total cost received by the writing party (or parties) was $30.4K, with a price of $6080.0 per contract. There were 93 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRTX

5 Health Care Stocks Whale Activity In Today's Session

Mizuho analyst Anthony Petrone maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and lowers the price target from $100 to $98.

Mizuho Maintains Outperform on Medtronic, Lowers Price Target to $98

RBC Capital analyst Shagun Singh maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and lowers the price target from $105 to $101.

RBC Capital Maintains Outperform on Medtronic, Lowers Price Target to $101

Press Releases

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Earnings

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Medtronic announces intent to separate Diabetes business

Dividends

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Small Cap

AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names

Medtronic announces MiniMed as name for planned New Diabetes Company

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

Medtronic Board appoints Dr. Joon Lee as a new director

AVAI

BFLY

OBIO

PODD

RXRX

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

TransMedics Group

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Leerink Partners

Mizuho

RBC Capital

Baird

Truist Securities

Screenshot 2024-10-03 at 5.30.47 PM

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Comments

Medtronic

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL